Oruka Therapeutics’ (ORKA) Buy Rating Reiterated at BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They presently have a $151.00 target price on the stock. BTIG Research‘s price objective would indicate a potential upside of 88.94% from the stock’s previous close.

ORKA has been the subject of several other reports. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Mizuho set a $120.00 price target on Oruka Therapeutics in a report on Thursday, September 3rd. Finally, Guggenheim restated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $128.91.

Oruka Therapeutics Trading Up 1.0%

Oruka Therapeutics stock traded up $0.83 during trading hours on Monday, reaching $79.92. 953,374 shares of the stock were exchanged, compared to its average volume of 1,087,958. Oruka Therapeutics has a twelve month low of $25.11 and a twelve month high of $115.51. The company has a market cap of $5.29 billion, a P/E ratio of -39.37 and a beta of -0.37. The stock has a 50 day moving average of $91.32 and a two-hundred day moving average of $80.65.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts expect that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, CEO Lawrence Klein sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the sale, the chief executive officer owned 925,580 shares in the company, valued at $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the sale, the insider directly owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 154,950 shares of company stock worth $14,102,680 in the last three months. 23.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ORKA. Algert Global LLC increased its stake in shares of Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after buying an additional 180 shares during the period. GAMMA Investing LLC raised its holdings in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares during the last quarter. Nykredit A S acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $29,000. AlphaCentric Advisors LLC boosted its position in Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after buying an additional 626 shares during the period. Finally, Orion Capital Management LLC bought a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $91,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.